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Background:  robotic assisted videothoracoscopic surgery (RVATS) adoption has 
increased worldwide from 3.4% in 2010 to 17.5% in 2015. But in Latin America the 
literature is limited to a report of a series of 10 patients who underwent RVATS 
lobectomy one case report of an RVATS thymectomy from Brasil.  
Methods: this is a retrospective review of all RVATS performed in Bogotá 
Colombia since 2012. A single thoracic surgeon (R.B) performed all the operations 
at 3 institutions: Clínica de Marly, Fundación Clínica Shaio and Instituto Nacional 
de Cancerología. Preoperative, intraoperative, postoperative and pathology report 
variables were included. Patients were analized in 3 groups: patients who were 
subject to robotic RVATS pulmonary resections, patients who were subject to 
RVATS mediastinal surgeries and the patients who were subject to other RVATS 
procedures. Descriptive statistics were used to report the median and interquartile 
range (IQR) of the continuous variables, and number and percentage were used to 
describe categorical variables. The association between total operative time and 
the year the surgery was analized usign a linear regression model.  
Results: 47 patients underwent RVATS pulmonary resections. 72.3 % (n=34) of 
this patients underwent a RVATS lobectomy, the median total operative time was 
220 minutes (IQR 200 to 250), 6.4% (n=3) had intraoperative complications, and 
the most frequent histologic diagnosis was adenocarcinoma (n=24, 51.1%). Of 18 
patients who underwent RVATS mediastinal surgeries, 50.0 % (n=9) had RVATS 
thymectomy, the median total operative time was 195.5 minutes (IQR 131 to 221) 
and two patients (11.1%) had intraoperative complications. The linear regression 
model of the association between total operative time and the year the surgery was 
performed showed a 10.3 minute reduction per year (p 0.006).  
Conclusions: this is the second series of RVATS published in Latin America and 




Minimally invasive surgery (MIS) has demonstrated substantial benefits compared 
with thoracotomy  and sternotomy for thoracic procedures, this benefits include 
lower complication rates, shorter hospital length of stay (LOS) and faster recovery. 
Robotic-assisted videothoracoscopic surgery (RVATS) is the most recent MIS 
technique and compared with other MIS platforms, RVATS provides three 
dimensional visualization, seven degrees of freedom of motion and improved visual 
haptics (1).  
In 2015, more than 6000 robotic lobectomies were performed in the United States, 
and more than 8600 were done worldwide(2). In contrast, the latin american 
literature is scarse, there is a series RVATS pulmonary lobectomies reported from 
Brasil with 10 patients and good perioperative outcomes but long term results are 
pending (3) and one case report of robotic assisted thymectomy also from Brasil 
(4). In Colombia the first robotic lobectomy was performed in 2012 (5) when the da 
Vinci Robotic System was aquired, since then 69 RVATS have been performed. 
The objective of this article is to report the first experience with RVATS for different 




This is a retrospective review of all the RVATS performed in Bogotá Colombia 
since 2012 when the first Da Vinci robot was aquired. A single thoracic surgeon 
(R.B) performed all the operations at 3 institutions, Clínica Marly, Clínica Shaio and 
Instituto Nacional de Cancerología. The operations were completed with the 
patients under general anesthesia and lung isolation, using either a 3-arm or 4-arm 
robotic technique.  All the patients who underwents RVATS from april 2012 to 
august 2018 were selected. The clinical histories, surgical descriptions and 
pathology results were reviewed and the variables were collected in a pre-design 
format.  
Preoperative variables included age in years and sex. Intraoperative variables 
included lesion location and resection type; docking time, console time and total 
operative time in minutes (min). The docking time was defined as time from the first 
skin incision to the start of driving the robotic arm while seated at the console, the 
console time was defined as the time that principal surgeon drove the robotic arm 
while seated at the console and performed the intrathoracic procedures and total 
operative time was measured from the first skin incision to skin closure. Blood loss 
in mililiters (mL), convertion rate to thoracotomy or sternotomy and intraoperative 
complications were also measured. Postoperative variables collected included 
chest tube duration in hours (Chest tubes were removed during the hospital stay as 
soon as the drainage was less than 100 mL/day and no air leaks were present), 
postoperative complications, days of hospital LOS, in hospital mortality, 90 day 
mortality and follow up time in months. Lastly the variables collected from the 
pathology report were histology of the tumor or lesion, median tumor size in 
milimeters (mm) and the stage of the disease for malignant pathologies 
complemented with images and clinical history. 
Patients were divided in 3 groups: patients who were subject to robotic RVATS 
pulmonary resections, patients who were subject to RVATS mediastinal surgeries 
and patients who were subject to other RVATS procedures which include plication 
of the diaphragm, sympathectomy and resection of a thoracic wall lesion. The 
variables were analized in each group separately.  
The data were collected using Excel software (Microsoft Corp) and analyzed using 
STATA 14. Descriptive statistics were used to report the medians and interquartile 
range (IQR) of the continuous variables were IQR lower value corresponds to the 
25% quartile and the higher value corresponds to the 75% quartile. Number and 
percentage were used to describe categorical variables. The association between 
total operative time and the year the surgery was performed was analized usign a 
linear regression model.  
 
Results 
RVATS pulmonary resections 
Between april 2012 and august 2018 a total of 69 patients underwent RVATS with 
the da Vinci Surgical System. From the 47 patients in which RVATS pulmonary 
resections were performed, the median age was 61 years (interquartile range (IQR 
50 to 73) and 27.7% (n=13) were men. The data for this group is presented in table 
1.  Tumor location was most prevalent in the right upper lobe (n=15, 31.9%), 72.3 
% (n=34) of patients underwent a RVATS lobectomy, and the remainder had 
segmental (n=2, 4.3%) or nonanatomic resections (n=5,10.6%). Two 
bronchoplasties were performed for two patients with a neuroendocrine tumor and 
a metastasic lesion from thyroid cancer. The median total operative time was 220 
minutes (IQR 200 to 250), the median console time was 125 minutes (IQR 110 to 
150) and the median blood loss was 100 ml (IQR 80 to 100). There were no 
convertions to thoracotomy and 6.4% (n=3) had intraoperative complications, that 
consisted in introperative bleeding that was adequeately controled. The median 
chest tube duration was 48 hours (IQR 48 to 67) and the median lenght of hospital 
stay was 3 days (IQR 2 to 4). The most frequent histologic diagnosis was 
adenocarcinoma (n=24, 51.1%), followed by benign lesions (n=9, 19.2%) and 
neuroendocrine tumors (n=5, 10.6%). The majority of patients had stage I disease  
(n=24, 64.9%). There was no inhospital mortalitiy and there was one death at 90 
days follow up. The mean follow-up time was 29 months (IQR 12 to 55) and during 
the follow-up time 6 (12.8%) patients died of metastasic disease. Two patients with 
marginal pulmonary function (FEV1 49% and 26%) underwent a RVATS lobectomy 
with good results. 
RVATS mediastinal procedures 
There were 18 patients who underwent RVATS mediastinal surgeries. In this group 
the median age was 50 years (IQR 39 to 59) and 22.2% (n=4) were men. The data 
for this group is presented in table 2.  Surgical main location was the anterior 
mediastinum (n=11, 61.1%) and 50.0 % (n=9) of patients underwent a RVATS 
thymectomy, 7 patients had miastenia gravis and 2 patients had thymomas. There 
were two esophageal leiomyoma resections and one bronchogenic cyst resection. 
The median total operative time was 195.5 minutes (IQR 131 to 221), the median 
console time was 107.5 minutes (IQR 95 to 125) and the median blood loss was 
50mL (IQR 20 to 90). There were no convertions to sternotomy and two patients 
(11.1%) had intraoperative complications caused by bleeding. The median lenght 
of hospital stay was 2.5 days (IQR 2 to 3) and the median chest tube duration was 
48 hours (IQR 24 to 68). There ware no in hospital mortalities or 90 day mortalities 
and the mean follow-up time was 14 months (IQR 5 to 24).  There were no deaths 
during the follow-up time. 
Other RVATS procedures 
There were four patients who underwent other type of surgeries that consisted of 
two plicatures of the diaphragm, one sympathectomy and one thoracic wall 
resection of a patient who had a metastasic lesion from multiple mieloma (table 3). 
There were no convertions, intraoperative complications, postoperative 
complications, in hospital mortality or 90 day mortality among this patients. 
 
Time trend for surgery time 
 
We performed a linear regression to analize the association between total 
operative time and the year the surgery was perfomed (figure 1). This figure shows 
a 10.3 minute reduction per year of surgery with a 95% confidence interval  
between 3.1 minutes and 17.5 minutes and a p values of 0.006. 
 
There were seven patients who had missing data on in hospital mortality because 
they were either lost to follow up or had not completed the 90 days of follow up at 
the moment of data collection and one patient has missing data on blood loss.  
 
Discussion 
In 2015 RVATS lobectomies accounted for 17.5% of elective lobectomies which 
represents a fivefold increase in RVATS adoption rate from the 3.4% of 
lobectomies in 2010 reported by Kent and colleagues (6). The increased adoption 
of RVATS appears to result from a shift from the open approach, given that the 
rate of video assisted thoracoscopic surgeries (VATS) have remained unchanged 
at approximately 40% (6). The reasons for this limited acceptance of VATS are 
multifactorial and include restricted vision secondary to two dimentional nature of 
conventional laparoscopes, and limited range of motion of instruments due to size 
and design. RVATS has been studied to overcome these limitations because it 
offers several technical advantages such as three dimensional high definition field 
of view, tremor filtration, augmented dexterity, and better ergonomics (7–10). 
Patients undergoing VATS suffer from fewer complications, have less pain and 
blood loss, and recover faster compared to patients undergoing thoracotomy for 
different thoracic pathologies (7). In multivariate analysis, VATS was associated 
independently with a reduced risk of complications  (11). Several restrospective 
comparative studies published between 2008 and 2018 have demostrated that 
RVATS lobectomy is safe and effective and has 30-day mortality comparable to 
that of VATS (12–15) and better outcomes compared to thoracotomy (6,16,17) with 
similar long term survival (18,19). When single large national and statewide 
databases are analized, RVATS yields lower morbidity (6) and lower mortality than 
both thoracotomy and VATS (16,17). Two studies found lower convertions rates 
with RVATS compared to VATS (14,15). and some studies suggest that RVATS 
has better outcomes in patients with marginal pulmonary function (20) and that is 
safe for older patients (21). In our series two patients with marginal pulmonary 
function had RVATS lobectomy with good results. Some systematic reviews and 
metanalysis of retrospective observational studies found that perioperative 
morbidity and mortality were similar between patients who underwent lung 
resections by RATS and those who underwent VATS (8,9,11),  with a tendency 
towards shorter hospitalization time and drainage duration with RVATS(7).  
In this series we present the first report of RVATS in Colombia and the second and 
largest series reported so far in Latin America. RVATS lobectomies were 
performed using the method described by Dylewski (22) and the instrument 
position is shown in figure 2. Compared to the first series reported in Brasil, we 
have a higher female rate and the age distribution is similar, but we can not 
compare the perioperative results because they did not report median values of 
these variables. Most of their patients had chest tube drainage from 24 to 48 hours 
and lenght of hospital stay less than 48 hours, which have concordance with our 
results (3).  Our results are comparable to those reported in the international 
literature, with the exception of sex distribution because our series has more 
females compared to others (9). Our total operative time is also comparable, the 
mean operative time in our study was 185 min and in the literature it ranges from 
107 to 241 minutes (8,9). As we know, there is a steep learning curve for RVATS, 
and operating time has been shown to significantly improve after the initial learning 
period (23,24), in this report we analized the total operative time by the year in 
which the surgical procedures were performed and the mean total time decreased 
during the six years of the estudy (figure 1). Convertion rate was 0% as reported in 
many series (25,26). Postoperative hospital LOS, duration of chest tube drainage, 
perioperative mortality, perioperative morbidity and blood loss in this series were 
comparable to those previously reported (8,9,27).  
Most surgeons offered RVATS to clinical stage I or II non small cell lung cancer, 
Veronesi et al. limited the maximum size to five centimeters,  Cerfolio et al. 
extended the indications to include larger size or preoperative chemoradiation and 
other surgeons allowed more advanced cases (28). Recent reports showed that 
more complicated cases needing bronchoplastic surgery were feasible for robotic 
surgery (29,30). In this series most of the patients with lung cancer diagnosis had 
stage I disease and we also report more complex surgical procedures such as two 
bronchoplasties with adequate perioperative outcomes. 
Mediastinal tumors are good candidates for robotic surgery. Several articles have 
shown that RVATS mediastinal mass resections including thymectomy are as good 
as VATS (31) and superior to transsternal resection, reducing intraoperative blood 
loss, postoperative complications, and hospital length of stay (32–34). RVATS for 
thymic epitelial tumors achieved comparable long-term oncologic outcomes (35).  
There are two metanalisys (36,37) and one systematic review  (38)comparing 
RVATS and VATS for thymectomy which show no difference with respect to 
conversion rate, hospital LOS, or postoperative morbidity. One metanalisys 
showed a tendency towards less hospital LOS and less chet tube drainage days 
with RVATS compared to VATS, but the power of the study was low, only seven 
studies were included (37) 
This series of RVATS for mediastinal surgeries have similar results compared with 
the literature. In the metanalysis by Buentzel et al the operation time ranged from 
97 to 224.2 minutes and in our study the mean total operative time was in this 
range (37). As in this series, most of the studies had 0% convertion rate, and short 
lenght of chest tube duration (37). The hospital LOS in the literature ranged from 
3.7 to 9.6 days, in this series this time was shorter with a mean of 2.5 days (37). In 
this report patients had minimum blood loss and none postoperative complications, 
simliar to other studies (39,40). 
The presented series brings to the thoracic robotic literature the second series of 
RVATS published in Latin America and the first published in Colombia, with 
comparable peritoperative results to other reports. We also present two patients 
who underwent RVATS bronchoplasties, showing that more complex procedures 
are feasible. And two patients with marginal pulmonary function that made the 
open approach impossible and the VATS approach very difficult, in this patients the 
RVATS optimization of precision and postoperative outcomes made the pulmonary 
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Figure 1. Linear regression showing a 10.3 reduction in total operative time by 
years of RVATS experience. 




Table 1. RVTAS pulmonary resections: patient characteristics and perioperative 
results. 
 
Table 2. RVATS mediastinal lesion resection: patient characteristics and 
perioperative results. 
 
Table 3. RVATS other procedures: patient characteristics and perioperative 
results.  
 
	  
